EXUMA Biotech

EXUMA, formerly known as F1 Oncology, is a clinical-stage biotechnology company discovering and developing CAR-T therapies for solid and liquid tumors.

EXUMA Biotechnology is committed to bringing to market CAR-T therapies for the treatment of cancer.

EXUMA was founded in Nov 2015 and is headquartered in West Palm Beach, Florida. The company has its international affiliates in China (Shanghai and Shenzhen), Grand Cayman, and across the US with sites in West Palm Beach and San Diego.


EXUMA's comprehensive, data-driven approach to candidate design and selection provides an optimized and efficient process to select the best CAR composition for a given indication amongst hundreds of thousands of rationally designed combinations.


Exuma leverages its global R&D footprint to discover, manufacture and develop gene delivery platforms and gene programs that may overcome the safety, efficacy, and scalability challenges of cellular therapies in solid tumor and hematologic malignancies.


Exuma's next-generation, subcutaneous, chemotherapy-free technology platform is being developed to test the ability of CAR-modified cells to form in the body from a synthetic lymph node and mount a systemic anti-tumor response without the complications of chemotherapy.


EXUMA is backed by MSD Partners, Americo Life, F1 BioVentures, Sinobioway, Sunterra Capital, and others. The company completed a $41M Series B2 round on Dec 21, 2021. This brings EXUMA's total funding to $107M to date. 



  • Year founded: 2015
  • Funding Info: $107M over 4 Rounds (Latest Funding Type: Series B2)
  • Yearly Revenue: NA
  • Employee Size: 11-50
  • Business Valuation: NA
  • City/Town: West Palm Beach
  • State: Florida
  • Country: United States
Related businesses